Background: Fluid management remains a major challenge of hemodialysis (HD) care, with serious implications for morbidity and mortality. Intradialytic fluid management is typically guided by blood pressure, an indirect resultant of hemodynamics status. Direct measurements of hemodynamic parameters may improve cardiovascular outcomes by providing rational bases for intervention. We compare stroke volume (SV) measurements using a noninvasive, regional biompedance cardiography device (NiCaS) with Doppler echocardiography (Echo) in HD setting.
INTRODUCTION
Despite significant technological advances in hemodialysis (HD), morbidity and mortality rates are high in end-stage kidney disease (ESKD) patients undergoing maintenance HD treatments. 1 Depending on the definition used, intradialytic hypotension (IDH) occurs in 15% to 50% of HD sessions, most often in relation to the ultrafiltration (UF) rate. 2 IDH is also associated with increased cardiovascular and neurological morbidity and mortality. [3] [4] [5] Specifically, UF rates of >13 mL/h/kg are significantly associated with increased all-cause and cardiovascular-related mortality with adjusted hazard ratios of 1.59 and 1.71, respectively. 6 Equally important, though often underappreciated, is that repeated IDH events can result in nausea, muscle cramps, fainting, and anxiety; while longterm effects of IDH can result in dyspnea, fatigue, cognitive impairment, and exercise intolerance -all negatively affecting quality of life. 7 Recent studies demonstrate that cardiac injury and myocardial "stunning" occur repeatedly during dialysis. 7 Thus, the incidence of IDH events is still high despite major technical advances in HD technology. Consequently, fluid management must become a central concern of HD treatments, 8, 9 particularly as the population ages.
The single, most important measurement available to clinicians for guiding fluid management is blood pressure (BP) which is determined by cardiovascular hemodynamics. In patients with healthy kidneys, autonomous and cardiovascular changes occur in order to maintain the BP necessary for adequate organ perfusion in the face of varying blood volumes. However, because several intrinsic control mechanisms tightly regulate BP in response to UF-induced blood volume reduction, periodic BP measurements during HD are of little use in predicting IDH. Peripheral vascular and cardiac abnormalities in chronic HD patients are common, 7 leading to chronic interdialytic high BP mostly due to hypervolemia and IDH due to hypovolemia. Therefore, routine monitoring during HD treatments that include blood volume monitoring in addition to BP and/or other hemodynamic parameters may improve these poor outcomes. 10, 11 An upper limit of UF rate has been recommended as a Medicare required quality metric since high UF rates are associated with poor outcomes. There are no prospective studies that support this recommendation and likely the epidemiological association is more complicated, and, in addition, individual patient factors need to be taken into account.
Sensors integrated in dialysis machines are able to track the concentration of various blood components, such as hematocrit, with high accuracy and resolution and to derive relative blood volume (RBV) changes. [12] [13] [14] [15] [16] [17] However, RBV is an incomplete measure of absolute blood volume (ABV) status. Its clinical value remains controversial and studies have not definitely shown that measuring RBV leads to improved treatment outcomes. 18 The reference technique (the "gold standard") for ABV measurement is based on radioactive tracer dilution for the 2 major components of blood (the red blood cells and the plasma). Unfortunately, this technique is invasive, costly, and impractical in routine outpatient dialysis care. 19 Hemodynamic parameters, such as stroke volume (SV) and cardiac output (CO), are an essential component of fluid management in cardiac and intensive critical unit settings. Measurement techniques can be broadly classified as 20 : invasive: pulmonary artery thermodilution; minimally invasive: pulse power or contour analysis, ultrasound dilution, partial gas rebreathing, transesophgeal echocardiography; and noninvasive: photoelectric plethysmography, thoracic bioimpedance, Doppler-based, endotracheal CO monitor, and bioimpedance cardiography. The invasive Swan-Ganz pulmonary artery catheterization (PAC) thermodilution technique is considered the gold standard despite controversies. 20 Consequently, a critical need exists for a noninvasive, inexpensive, reliable, and practical technique for measuring hemodynamic parameters in HD. One such technique is bioimpedance cardiography 21 which was applied in HD as early as 1977. 22 A regional bioimpedance cardiography device (NiCaS, NI Medical, Israel) has been validated in cardiac care against PAC 21, 23, 24 and Doppler echocardiography, 25 and shown to have better accuracy and precision compared with thoracic bioimpedance 21 and modified-Fick 23 techniques. Recent hemodynamic studies in HD settings include baroreceptor sensitivity using Finometer (Finapres Medical Systems), 26 cardiomyopathy using cardiac and aortic MRI, 27 and ischemic brain injury using molecular MRI. 28 The aim of this study was to compare NiCaS against the noninvasive and widely available Echocardiography 29 technique in the HD setting.
STUDY DESIGN AND METHODS

Patients
Seventeen (17) patients were enrolled in January 2017 at a single outpatient HD facility in the northeast United States. In each patient, we performed simultaneous SV measurements using NiCaS and Echo during 2 different HD treatments in 1 week. Simultaneous NiCaS and Echo measurements were taken during the first hour of the HD session and then repeated during the last hour, within each HD treatment. All Echo-SV and NiCaS-SV readings were independently carried out by 2 technicians who were double blinded to each other. Inclusion criteria included ESKD patients (age 18) undergoing chronic maintenance HD. Exclusion criteria included severe aortic valve regurgitation and/or aortic stenosis, aortic aneurysm, severe arrhythmia, and heart rate > 130 beats/min. The Schulman Institutional Review Board, Cincinnati, OH, USA (IRB #201606285), approved the study. All patients gave written informed consent before enrollment.
Echocardiography measurements
Stroke volume was derived using Philips CX50 CompactXtreme pulsed wave Doppler measuring ventricular outflow tract (LVOT) in either the apical long axis or 5-chamber view and the velocity time integral (VTI). LVOT diameter was measured in the parasternal long axis view in systole, with VTI providing information regarding blood velocity across the duration of systole in units of centimeter (cm). Stroke volume is calculated as the product of cross sectional area times the velocity of blood flow. Thus, Figure 1 for a representative SV measurement panel.
Regional bioimpedance cardiography (NiCaS) measurements
Stroke Volume is measured by applying alternating electrical current of 1.4 mA with a 30 kHz frequency through the patient body via 2 pairs of tetrapolar sensors, 1 pair placed on the wrist of the hand without the arteriovenous fistula or graft above the radial pulse and the other pair on the contralateral ankle above the posterior tibial arterial pulse. SV is calculated by Frinerman's formula 24, 25 :
where dR is impedance change of the arterial system as a result of arterial system expansion during the systole, R is basal resistance, q is blood electrical resistance, L is patient's height, Ri is corrected basal resistance according to gender and age, KW is the correction of weight according to ideal values, HF is a hydration factor which takes into account the body water composition, a 1 b is the ECG R-R wave interval, and b is the diastolic time interval. SV is automatically calculated every 20 second and the average of 3 measurements obtained consecutively during 60 seconds of monitoring (see Figure 2 ). 
Statistical analysis
We report descriptive statistics as means with 95% confidence intervals (CI) adjusted for repeated measures at the patient level when appropriate, medians with interquartile ranges (the 25th and 75th percentiles), or counts and frequencies. Pearson's correlation coefficient evaluated the relation between NiCaS and Echo SV measurements. To account for repeated measurements, the Pearson correlation coefficient was calculated as a weighted average correlation coefficient, weighted by the number of repeated measurements observed for each patient. For variables with repeated measurements, a "between patients" correlation coefficient was derived to account for the serial correlation. Comparisons between 2 correlations were made by a method described in Ref. 30 . P values were then calculated based on Bland and Altman 31 where P values <0.05 were considered to be statistically significant. In addition, a Bland-Altman plot was created to assess the agreement between NiCaS and Echo SV measurements, and the limits of agreement were also adjusted for repeated measures within patients as well. 32, 33 In addition, we derived differences from the first and last measures of SV with both the NiCaS and Echo devices and plotted the percent change from the first measure as a 4-Quardrant Plot. 34, 35 To compare means, we use a modified version of the paired t-test where we adjust for repeated measures within each patient at multiple time periods using robust variance estimators. 36 A linear regression model with no constant term and standard errors adjusted to take clustering at the patient level into account was developed between the predictor Echo and estimator (dependent variable) NiCaS. 36 An assessment of how the slope (the coefficient of Echo) differed from one (1) 
RESULTS
Seventeen (17) patients were measured resulting in a total of 64 observations (33 during the first hour and 31 during the last hour of HD treatment see Table 1 ). Baseline characteristics of the study population are summarized in Table 1 .
The mean (95% CI) values of measured Echo and NiCaS SV were 58.0 (50.1, 65.8) mL and 56.7 (49.4, 64.0) mL, respectively, P value 5 0.36. Pearson's correlation coefficient for measurements taken during the first and last hours were r 5 0.93, P < 0.001 (n 5 33) and r 5 0.92, P < 0.001 (n 5 31), respectively. Also, the overall Pearson correlation coefficient was r 5 0.92, P < 0.001. Mean (95% CI) total fluid removed at the time of SV measurements during the first and last hours of HD treatment were 1001 (617, 1384) mL and 2142 (1539, 2745) mL, respectively.
Adjusted linear regression with no constant term gave NiCaS SV 5 0.97 3 Echo SV, 95% CI 5 (0.91, 1.02), P < 0.001 (See Figure 3) . The slope (coefficient) of Echo did not differ from 1 (P 5 0.20) which implies that NiCaS and Echo were similar across the observed range of values. The Bland-Altman plot showed similar results (see Figure 4) . No visible trend in the differences between measures seemed apparent. The limits of agreement (95% CI) between the NiCaS and Echo SV measurements were (211.6, 14.1) mL and the mean difference was 1.3 mL (Figure 4) . Only 1 patient out of 17 (5.9%) had the majority of the differences between their observations (3 out of 4 differences) fall outside the limits of agreement.
The 4-Quadrant plot in Figure 5 shows SV percent change from the first to last hours of treatments for both NiCaS and Echo for 27 observations from 15 patients (observations with a single measurement were excluded). Points falling in the upper left and lower right quadrants are discordant (i.e., 1 measurement shows a temporal increase while the other shows a decrease or vice versa). Only 2 out of 27 (7.4%) of these observations were in these quadrants. Additionally, the correlation of the percent change between the 2 methods was high, r 5 0.77, P < 0.001.
The change in mean arterial pressure (MAP) between first and last hours of treatments were compared with SV change between first and last hours of treatments (see Figure 6 ). Percent MAP difference was uncorrelated with percent SV difference: r 5 20.03, P 5 0.93 and r 5 0.08, P 5 0.79 for NiCaS and Echo, respectively.
DISCUSSION
The main finding of this study is that the measurement of SV using NiCaS is strongly correlated with SV measured using Echo in ESKD patients undergoing maintenance HD. This correlation remains strong in the subgroup analysis during first-hour observations or last-hour observations, suggesting that the degree of UF did not have a significant effect on NiCaS measurements. The strong correlation is confirmed and substantiated by a nearly unity relation between the 2 techniques as seen in the linear regression analysis, and by the general agreement of the 2 methods in the Bland-Altman plot. Furthermore, the 4-Quadrant plot showed that the changes in SV over time as measured by the 2 devices trended in the same directions (i.e., both showed either increases or decreases over time) and tended to show similar percent changes over time as well. Echocardiography is a well-established diagnostic tool for assessing cardiovascular status, however, it is operator-dependent and is not considered a practical option for routine assessment of hemodynamic parameters in HD. In contrast, NiCaS provides continuous, noninvasive SV measurement using a patientfriendly configuration in which 2 sensors are placed in the periphery (wrist and contralateral ankle). The signals measured in thoracic impedance cardiography whose sensors are placed on the thorax, in contrast to sensors that measure signals in the peripheral arterial system, are affected by noise distortion from various sources such as the lungs, vena cava, aorta, and movement of the heart. Note that we compared SV since it is the measured parameter. However, CO which is the product of SV and measured heart rate, is also available to the clinician.
Strengths and limitations of the study warrant comment. Strengths include being the first of its kind validation of NiCaS in an HD setting, study design capturing withinpatient SV hemodynamics during an HD treatment, and use of rigorous statistical methods accounting for repeated measures within patients. Limitations include a singlecenter design and a high percentage of a white race cohort. A larger, multi-center study on a more diverse population should resolve such limitations.
Blood pressure is the only diagnostic tool available during routine HD in the management of hypertension and hypotension. Arguably, BP data alone cannot accurately represent cardiovascular status. This study confirmed that BP changes during first and last hours of treatments are not correlated with SV changes during the same periods. Hence, SV measurements can offer an added diagnostic dimension to that offered by BP data alone. For example, the device permits the calculation of peripheral resistance from CO and BP. Decrease in resistance occurs commonly in the HD treatment, particularly in diabetic patients, and can be managed by cooling the dialysate or by use of adrenergic agonists such as midodrine, therapeutically or prophylactically.
In conclusion, NiCaS technology is well correlated with echocardiography, and offers a practical, noninvasive approach at the bedside for measuring hemodynamic parameters in the ESKD population during HD treatments. This technology has the potential to offer new physiological insights into hemodynamics during HD. This could facilitate the development of personalized intervention which sets optimal dry weight targets and adjusts UF rates in reaction to changes in hemodynamic parameters. Thereby, the opportunity exists to improve cardiovascular outcomes in ESKD.
